New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
17:02 EDTSQNMSequenom CMM's announces results of RetnaGene AMD
Sequenom announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine, presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago. This Sequenom CMM laboratory-developed genetic test combines patient disease stage with patient genetic variation to evaluate the risk of a patient with early or intermediate AMD to progress to advanced choroidal neovascularization, or CNV, disease within 2, 5, and 10 years. CNV is the most common form of 'wet' advanced age-related macular degeneration, or AMD, in which new blood vessels in the eye leak fluid, compromising central vision. Advanced disease impacts approximately 10% of AMD patients, but is associated with 90 percent of vision loss in AMD.
News For SQNM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
17:39 EDTSQNMSequenom launches the HerediT test in collaboration with Recombine
Sequenom's wholly owned subsidiary, Sequenom Laboratories, and Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, launched the HerediT UNIVERSAL carrier screening test as a service to ordering physicians. The HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations.
07:59 EDTSQNMSequenom management to meet with William Blair
Subscribe for More Information
March 17, 2015
07:05 EDTSQNMSequenom elects Kenneth Buechler as Chairman of the Board
Sequenom elected Kenneth Buechler as Chairman of the Board, effective April 1, 2015. Buechler succeeds Harry Hixson who will retire from the position effective March 31 after 11 years of service. Incoming chairman, Dr. Buechler, has served on the board of directors since December 2009. Prior to joining Sequenom's board, he served as President and Chief Scientific Officer of Biosite Incorporated, which he co-founded.
March 16, 2015
05:40 EDTSQNMIllumina files patent infringement suit in UK regarding NIPT patents
Illumina (ILMN) announced that it and its wholly-owned subsidiary, Verinata Health have filed a patent infringement suit against Premaitha Health in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent 0 994 963 B2 and European Patent 1 981 995 B1, which are exclusively licensed to Illumina from Sequenom (SQNM), and The Board of Trustees of Leland Stanford Junior University, respectively. Stanford is joined in the suit as a necessary party because it is the registered owner of the European Patent 1 981 995 B1. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing. The suit accuses Premaitha’s IONA Test of infringement, including its use of next-generation sequencing to analyze cell-free fetal DNA from a sample of maternal blood.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use